## Regulatory read-through: FDA is effectively re-setting the evidentiary bar for AMT-130 uniQure’s latest disclosure makes the regulatory message unusually explicit: the FDA “cannot agree” that AMT-130’s Phase I/II package—when benchmarked against an **external control**—is sufficient to serve as the *primary* evidence of effectiveness for a marketing application. ["cannot agree"](0001104659-26-021890|1) ["compared to an external control"](0001104659-26-021890|1) ["primary evidence of effectiveness"](0001104659-26-021890|1) Between the lines, that’s not a debate about *whether* the dataset is interesting—it’s the agency telegraphing that the *comparative framework* (propensity/external control) won’t carry the approval burden on its own, even after extensive prior alignment work. ["Phase I/II studies, compared to an external control, are sufficient"](0001104659-26-021890|1) ## The “sham-controlled” recommendation is a timeline-and-capital statement (not just trial design) The FDA “strongly recommended” a **prospective, randomized, double-blind, sham surgery-controlled** study. ["strongly recommended"](0001104659-26-021890|1) ["randomized, double-blind, sham surgery-controlled"](0001104659-26-021890|1) That matters because sham-controlled neurosurgical trials are operationally heavy (site readiness, procedure standardization, recruitment friction), and—critically—this is the agency describing the study it wants as the core registrational backbone, not a post-approval clean-up. ["prospective, randomized"](0001104659-26-021890|1) ["sham surgery-controlled study"](0001104659-26-021890|1) uniQure is signaling it’s not conceding the point outright—but it is pivoting into negotiation mode around Phase III, with a planned Type B meeting request in Q2 2026. ["plans to request a Type B meeting in the second quarter of 2026"](0001104659-26-021890|1) ## Hidden alpha angle: the *real* asset may be durability + mechanistic coherence—if they can re-package it into an FDA-native design The company is still emphasizing the “strength and durability” of its AMT-130 dataset even while acknowledging misalignment on pathway. ["remain confident in the strength and durability"](0001104659-26-021890|1) ["not reached alignment with the FDA on an approval pathway"](0001104659-26-021890|1) In parallel, it highlighted updated analytical work presented Feb 23, 2026 arguing that **clinical covariates** can substitute for baseline striatal volume in predicting progression—importantly, using the same covariates employed to match treated patients to the external comparator cohort. ["propensity score methodology using clinical covariates"](0001104659-26-021890|1) ["same as those used in the 3-year data analysis"](0001104659-26-021890|1) The “alpha” opportunity is that these analytical investments aren’t wasted if Phase III is required: they can inform *enrichment*, stratification, endpoint sensitivity, and powering assumptions—i.e., make a sham-controlled program smaller/more efficient than the market may fear, *if* FDA accepts the statistical framing inside a randomized construct. ## Financial posture: uniQure can absorb the reset—at least on paper Management is explicit that **cash, cash equivalents, and current investment securities** were ~$622.5 million at Dec. 31, 2025 and are expected to fund operations into **2H 2029**. ["$622.5 million"](0001104659-26-021890|1) ["expected to fund operations into the second half of 2029"](0001104659-26-021890|1) The financial statements embedded in the same disclosure show the composition: $80.2 million cash and cash equivalents plus $542.3 million current investment securities (computed total ≈ $622.5 million). ["Cash and cash equivalents $ 80,240"](0001104659-26-021890|1) ["Current investment securities 542,301"](0001104659-26-021890|1) Operationally, 2025 revenue was $16.1 million and net loss was ~$199.0 million—so the runway claim is doing a lot of work in reassuring investors that the company can fund a heavier Phase III ask without immediately returning to the market. ["Revenue for the year ended December 31, 2025 was $16.1 million"](0001104659-26-021890|1) ["net loss for the year ending December 31, 2025, was $199.0 million"](0001104659-26-021890|1) ## What to watch next (where incremental “edge” could emerge) 1. **Type B meeting outcomes (Q2 2026 request):** any FDA openness to hybrid designs, endpoint strategy, or accelerated constructs inside a randomized framework will move perceived time-to-market. ["plans to request a Type B meeting in the second quarter of 2026"](0001104659-26-021890|1) 2. **Whether the “strongly recommended” sham trial becomes mandatory vs. modifiable:** the exact wording suggests FDA preference is strong—investors should assume the default path is a randomized sham-controlled Phase III unless negotiations materially change the posture. ["strongly recommended"](0001104659-26-021890|1) 3. **Cash discipline vs. commercialization readiness:** SG&A spending in 2025 included costs to support preparation for planned U.S. commercialization of AMT-130—an indicator the company had been gearing up for nearer-term launch before the FDA reset. ["incurred to support the preparation of the planned commercialization of AMT-130 in the United States"](0001104659-26-021890|1)

## Regulatory read-through: FDA is effectively re-setting the evidentiary bar for AMT-130 uniQure’s latest disclosure makes the regulatory message unusually explicit: the FDA “cannot agree” that AMT-130’s Phase I/II package—when benchmarked against an **external control**—is sufficient to serve as the *primary* evidence of effectiveness for a marketing application. ["cannot agree"](0001104659-26-021890|1) ["compared to an external control"](0001104659-26-021890|1) ["primary evidence of effectiveness"](0001104659-26-021890|1) Between the lines, that’s not a debate about *whether* the dataset is interesting—it’s the agency telegraphing that the *comparative framework* (propensity/external control) won’t carry the approval burden on its own, even after extensive prior alignment work. ["Phase I/II studies, compared to an external control, are sufficient"](0001104659-26-021890|1) ## The “sham-controlled” recommendation is a timeline-and-capital statement (not just trial design) The FDA “strongly recommended” a **prospective, randomized, double-blind, sham surgery-controlled** study. ["strongly recommended"](0001104659-26-021890|1) ["randomized, double-blind, sham surgery-controlled"](0001104659-26-021890|1) That matters because sham-controlled neurosurgical trials are operationally heavy (site readiness, procedure standardization, recruitment friction), and—critically—this is the agency describing the study it wants as the core registrational backbone, not a post-approval clean-up. ["prospective, randomized"](0001104659-26-021890|1) ["sham surgery-controlled study"](0001104659-26-021890|1) uniQure is signaling it’s not conceding the point outright—but it is pivoting into negotiation mode around Phase III, with a planned Type B meeting request in Q2 2026. ["plans to request a Type B meeting in the second quarter of 2026"](0001104659-26-021890|1) ## Hidden alpha angle: the *real* asset may be durability + mechanistic coherence—if they can re-package it into an FDA-native design The company is still emphasizing the “strength and durability” of its AMT-130 dataset even while acknowledging misalignment on pathway. ["remain confident in the strength and durability"](0001104659-26-021890|1) ["not reached alignment with the FDA on an approval pathway"](0001104659-26-021890|1) In parallel, it highlighted updated analytical work presented Feb 23, 2026 arguing that **clinical covariates** can substitute for baseline striatal volume in predicting progression—importantly, using the same covariates employed to match treated patients to the external comparator cohort. ["propensity score methodology using clinical covariates"](0001104659-26-021890|1) ["same as those used in the 3-year data analysis"](0001104659-26-021890|1) The “alpha” opportunity is that these analytical investments aren’t wasted if Phase III is required: they can inform *enrichment*, stratification, endpoint sensitivity, and powering assumptions—i.e., make a sham-controlled program smaller/more efficient than the market may fear, *if* FDA accepts the statistical framing inside a randomized construct. ## Financial posture: uniQure can absorb the reset—at least on paper Management is explicit that **cash, cash equivalents, and current investment securities** were ~$622.5 million at Dec. 31, 2025 and are expected to fund operations into **2H 2029**. ["$622.5 million"](0001104659-26-021890|1) ["expected to fund operations into the second half of 2029"](0001104659-26-021890|1) The financial statements embedded in the same disclosure show the composition: $80.2 million cash and cash equivalents plus $542.3 million current investment securities (computed total ≈ $622.5 million). ["Cash and cash equivalents $ 80,240"](0001104659-26-021890|1) ["Current investment securities 542,301"](0001104659-26-021890|1) Operationally, 2025 revenue was $16.1 million and net loss was ~$199.0 million—so the runway claim is doing a lot of work in reassuring investors that the company can fund a heavier Phase III ask without immediately returning to the market. ["Revenue for the year ended December 31, 2025 was $16.1 million"](0001104659-26-021890|1) ["net loss for the year ending December 31, 2025, was $199.0 million"](0001104659-26-021890|1) ## What to watch next (where incremental “edge” could emerge) 1. **Type B meeting outcomes (Q2 2026 request):** any FDA openness to hybrid designs, endpoint strategy, or accelerated constructs inside a randomized framework will move perceived time-to-market. ["plans to request a Type B meeting in the second quarter of 2026"](0001104659-26-021890|1) 2. **Whether the “strongly recommended” sham trial becomes mandatory vs. modifiable:** the exact wording suggests FDA preference is strong—investors should assume the default path is a randomized sham-controlled Phase III unless negotiations materially change the posture. ["strongly recommended"](0001104659-26-021890|1) 3. **Cash discipline vs. commercialization readiness:** SG&A spending in 2025 included costs to support preparation for planned U.S. commercialization of AMT-130—an indicator the company had been gearing up for nearer-term launch before the FDA reset. ["incurred to support the preparation of the planned commercialization of AMT-130 in the United States"](0001104659-26-021890|1)